Elanco Animal Health Incorporated announced on October 7, 2024, that the U.S. Food and Drug Administration (FDA) has approved Credelio Quattro (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets). This product offers the broadest approved canine oral parasiticide protection, covering six types of parasites including fleas, ticks, heartworms, roundworms, hookworms, and tapeworms.
Credelio Quattro is a single, monthly chewable tablet indicated for dogs eight weeks of age or older and weighing 3.3 pounds or greater. Elanco's President and CEO, Jeff Simmons, highlighted this as a milestone in the company's innovation era, marking the third of three approvals for blockbuster potential products in the U.S. this year.
The introduction of Credelio Quattro strengthens Elanco's diverse portfolio of parasiticides, providing veterinarians and pet owners with an innovative solution. Elanco expects Credelio Quattro to launch in the first quarter of 2025, targeting the fastest-growing segment of the parasiticide market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.